Immunotherapy combo shows promise for Hard-to-Treat prostate cancer
NCT ID NCT04717154
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested two immunotherapy drugs, ipilimumab and nivolumab, in 69 men with a specific type of advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow disease progression. Participants received four cycles of both drugs, followed by nivolumab alone for up to a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ipilimumab and nivolumab (immunotherapy drugs)
What this could lead to
If successful, this could offer a new treatment option that helps control advanced prostate cancer by using the immune system to fight the disease.
What could go wrong
This is an early-phase trial with only 69 participants, so results may not apply to all patients. Immunotherapy can cause serious side effects like inflammation of organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Radboudumc
Nijmegen, Gelderland, 6525GA, Netherlands